RESISTANCE TO AMOXICILLIN, CLARITHROMYCIN AND CIPROFLOXACIN OF Helicobacter pylori ISOLATED FROM SOUTHERN BRAZIL PATIENTS

Picoli, Simone Ulrich; Mazzoleni, Luiz Edmundo; Fernández, Heriberto; Bona, Laura Renata de; Neuhauss, Erli; Longo, Larisse; Prolla, João Carlos

doi:10.1590/s0036-46652014000300003

Cited by 29 publications

(23 citation statements)

References 27 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…H. pylori shows varied antibiotic susceptibility patterns in various geographical locations; moreover, this bacterium has been substantially influenced by the prior use of these drugs (Han et al, 1999). Previous studies conducted in Brazil have reported varying rates of H. pylori resistance to clarithromycin, ranging from 11.1 to 17.3% (Prazeres Magalhães et al, 2002;Eisig et al, 2011;Picoli et al, 2014). In this study, we could not show an association between the CYP2C19 genotype and efficacy of H. pylori eradication; however, H. pylori eradication was observed in a large proportion of patients (87.2%).…”

Section: Discussioncontrasting

confidence: 77%

Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia

et al. 2016

View full text Add to dashboard Cite

ABSTRACT. The aim of this study was to examine the effect of polymorphisms in the cytochrome P450 (CYP) 2C19 gene (CYP2C19) on the Helicobacter pylori eradication rate in Brazilian patients with functional dyspepsia. Adults diagnosed with functional dyspepsia based on the ROME III criteria and infected with H. pylori were recruited to this study. The patients were subjected to gastrointestinal endoscopy and the H. pylori status was defined when both urease test and histopathology results were negative or positive. The patients were treated with proton pump inhibitor-based triple therapy (omeprazole, amoxicillin, and clarithromycin). CYP2C19*2 and CYP2C19*3 were genotyped by polymerase chain reaction-restriction fragment length polymorphism. One hundred and forty-eight patients (81.8% women) with a mean (± SD) age of 46.1 (12.2) years were included in this study. Based on the CYP2C19 genotypes, the patients were classified as homozygous extensive metabolizer (HomEM; 67.6%), heterozygous extensive metabolizer (HetEM; 26.3%), or poor metabolizer (PM; 6.1%). The H. pylori eradication rates in patients with HomEM, HetEM, and PM were 85.0, 89.7, and 100.0% (P = 0.376), respectively. The included study population comprised a high frequency of patients carrying the HomEM genotype. Although the genotypes of CYP2C19 variants were not statistically significant, the results of this study suggest a possible effect of the PM genotype on the efficacy of H. pylori eradication.

show abstract

Section: Discussioncontrasting

confidence: 77%

Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This is in agreement with most of the local and international studies which reported rates that are similar to our results However, the reported MIC values of clarithromycin resistant H. pylori in our study were higher. [38,39]. In a study conducted by PCR for the detection of point mutations associated with clarithromycin resistance, similar rates were reported in Jordan [31].…”

supporting

confidence: 60%

“…In addition, the MIC values where less than 0.125 µg/ ml indicating that amoxicillin is a good choice of antimicrobial agents that should be included in the treatment regimens for H. pylori. In Brazil, resistance to amoxicillin has been detected in 29% of strains recovered from post-treatment [39]. However, many studies from other countries have shown that all strains examined are susceptible to amoxicillin [42,43].…”

mentioning

confidence: 99%

Molecular characterization and antibiotic susceptibility profiles of Helicobacter pylori isolated from patients with Gastrodeudenal diseases in Jordan

Abu-Qatouseh

Abu-Sini

Mayyas

et al. 2016

int. arab. j antimicrob. agents

View full text Add to dashboard Cite

Introduction: Helicobacter pylori is a major cause of more than 80% of chronic active gastritis and other gastrodeudonal diseases worldwide. Successful treatment of H. pylori routinely requires the use of multiple agents with different mechanisms including compounds inhibiting acid secretion in conjunction with antibiotics. However, recent data showed the emergence of resistant clinical strains particularly against metronidazole and clarithromycin. The aim of this study is to determine the prevalence of and the susceptibility of H. pylori isolates recovered from patients with gastrodeudonal diseases to several antimicrobial agents.

show abstract

“…Many studies on H. pylori primary antibiotic resistance rates were carried out over the last year. They are summarized in Table 1 [27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]. Although molecular in vitro testing gives a genotype that may not correspond to the phenotype in vivo, broad themes that do emerge are the increasing rates of clarithromycin and also fluoroquinolone resistance.…”

Section: Antimicrobial Resistancementioning

confidence: 99%

Treatment of Helicobacter pylori Infection 2015

et al. 2015

View full text Add to dashboard Cite

Many interesting articles have been published from many parts of the world over the last year assessing different issues around Helicobacter pylori eradication therapy. This article will address the published literature over the last year pertaining to the topic of treatment of H. pylori infection. The main themes that emerge are assessing the efficacy of standard triple therapy, as well as exploring new first-line treatments, mainly optimized nonbismuthand bismuth-containing quadruple therapies with some promising data also emerging on dual therapy. There was also considerable progress in investigating antibiotic resistance rates with much more data emerging from varied parts of the world compared to recent years. There have also been advances in the use of adjunctive therapies, especially probiotic therapies. Undoubtedly, the eradication of H. pylori remains a worthwhile goal to alleviate the burden of diseases caused by the complications of this infection, including dyspepsia, peptic ulcer disease, and gastric cancer. Triple TherapyA number of studies have been published this year, primarily from Asia, on standard triple therapy which remains the regimen recommended in the majority of published guidelines. A meta-analysis from China showed suboptimal eradication rates in this part of the world with a pooled rate of 74.5% which was inferior when compared to sequential therapy with relative risk (RR) = 0.863 [1]. Better, but still insufficient, eradication rates however were noted in Korea, with an overall eradication rate of 84% from 2005 to 2010 [2]. In Japan, while rates remain clearly suboptimal, eradication rates by per-protocol (PP) analysis have not changed between 2001 and 2010 although there has been a decline in eradication rates by intention-to-treat (ITT) analysis [3]. Another Japanese group from a region of higher clarithromycin resistance compared 7-day standard triple therapy with rabeprazole, amoxicillin, and clarithromycin (RAC) to rabeprazole, amoxicillin, and metronidazole (RAM). They found ITT eradication rates of 73% in the RAC group and 91% in the RAM group [4]. In other regions, a study in Nigeria found an eradication rate of 87% for triple therapy with no difference between 7 and 10 days of treatment [5]. An interesting study from Spain showed that when clarithromycin susceptibility testing is carried out prior to treatment, eradication rates reach 94% compared to 72% for empiric treatment, based on a 10-day regimen [6]. Similar findings emerged from a Japanese study where 97% eradication was achieved when antimicrobial susceptibility testing was carried out prior to treatment, and it was 95% eradication in a Korean study [7,8]. Another study from Spain examined the optimal first-line eradication regimen for patients with penicillin allergy and reported ITT eradication rates with omeprazole-clarithromycin-metronidazole of only 57% compared to 74% for PPI-bismuth-tetracyclinemetronidazole, with equivalent rates of compliance and adverse events. In this specific group for second-line treat...

show abstract

RESISTANCE TO AMOXICILLIN, CLARITHROMYCIN AND CIPROFLOXACIN OF Helicobacter pylori ISOLATED FROM SOUTHERN BRAZIL PATIENTS

Cited by 29 publications

References 27 publications

Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia

Influence of CYP2C19 on Helicobacter pylori eradication in Brazilian patients with functional dyspepsia

Molecular characterization and antibiotic susceptibility profiles of Helicobacter pylori isolated from patients with Gastrodeudenal diseases in Jordan

Treatment of Helicobacter pylori Infection 2015

Contact Info

Product

Resources

About